| CPSC | congenital paucity of secondary synaptic clefts [syndrome]; Consumer Products Safety Commission |
|---|---|
| ERPC | evacuation of retained products of conception |
| FbDP | fibrin degradation products |
| FgDP | fibrinogen degradation products |
| SPF | skin protection factor; specific-pathogen free; spectrophotofluorometer; S-phase fraction; split pro... |
| oncogene protein p65(gag-jun) | Transforming protein coded by jun oncogenes (genes, jun). This is a gag-onc fusion protein of about 65 kD derived from avian sarcoma virus. V-jun lacks a negative regulatory domain that regulates transcription in c-jun. (12 Dec 1998) |
|---|---|
| fusion proteins, gag-onc | General name for the translation products of a fusion mRNA consisting of a gag gene and a viral oncogene (v-onc). These products are thought to have the ability to transform cells. (12 Dec 1998) |
| fusion proteins, gag-pol | Polyprotein products of a fused portion of retroviral mRNA containing the gag and pol genes. The polyprotein is synthesised only five percent of the time since pol is out of frame with gag, and is generated by ribosomal frameshifting. (12 Dec 1998) |
| biological products | Complex pharmaceutical substances, preparations, or agents of organic origin, usually obtained by biological methods or assay, that depend for their action on the processes affecting immunity. They are used especially in diagnosis and treatment of disease (as vaccines or pollen extracts). Biological products are differentiated from biological factors in that the latter are compounds with biological or physiological activity made by living organisms. (12 Dec 1998) |
| blood products | Biopharmaceutical products purified from human blood, such as the blood clotting factor VIII used to treat haemophiliacs. (Recombinant factor VIII is also on the market.) The term also refers to biopharmaceuticals that act on blood or the cells that make blood. These products are often produced by the cells themselves, but in such tiny amounts that extracting them from blood is impractical, and so they are genetically engineered. (14 Nov 1997) |
| meat products | Articles of food which are derived by a process of manufacture from any portion of carcasses of any animal used for food (e.g., head cheese, sausage, scrapple). (12 Dec 1998) |
| glycosylation end products, advanced | Products derived from the nonenzymatic reaction of glucose and proteins in vivo that exhibit a yellow-brown pigmentation and an ability to participate in protein-protein cross-linking. These substances are involved in biological processes relating to protein turnover and it is believed that their excessive accumulation contributes to the chronic complications of diabetes mellitus. (12 Dec 1998) |
| waste products | Debris resulting from a process that is of no further use to the system producing it. The concept includes materials discharged from or stored in a system in inert form as a by-product of vital activities. (12 Dec 1998) |
| conventional forest products | Any commercial roundwood product (boards, dimension lumber, pulp and paper products) except fuelwood. (05 Dec 1998) |
| poultry products | Food products manufactured from poultry. (12 Dec 1998) |
| household products | Substances or materials used in the course of housekeeping or personal routine. (12 Dec 1998) |
| specialty chemicals and products | Chemicals and chemical products used in a research, industrial, or household setting. Included here are the specific drug preparations, as well as the substances involved in the manufacture and stabilization of pharmaceutical preparations and agricultural agents. (12 Dec 1998) |
| natural products | Naturally occurring compounds that are end products of secondary metabolism; often, they are unique compounds for particular organisms or classes of organisms. (05 Mar 2000) |
| dairy products | Raw and processed or manufactured milk and milk-derived products. These are usually from cows (bovine) but are also from goats, sheep, reindeer, and water buffalo. (12 Dec 1998) |
| orphan products | Drugs, biologicals, and medical devices (including diagnostic in vitro tests) that may be useful in common or rare diseases but which are not considered commercially viable. Synonym: orphan drugs. (05 Mar 2000) |